IMV to Present New Data at 2019 ASCO Annual Meeting From Its Phase 2 Clinical Trial Evaluating DPX-Survivac in Ovarian Cancer

Credit: Business Wire- Published on May 16, 2019
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that the American Society of Clinical Oncology (ASCO) has published an abstract on the Company’s clinical study evaluating its lead candidate, DPX-Survivac, in recurrent advanced ovarian cancer. The abstract was released online on the ASCO website yesterday in advance of ASCO’s annual meeting in Chicago, Illinois, taking place May 31 – June 4, 2019. The final

You are here

You might like